Cargando…

TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: A non-randomized retrospective study

BACKGROUND: Taxane-platinum therapy (TP) has replaced platinum-based therapy (PC or PAC, DNA damaging chemotherapy) in the postoperative treatment of ovarian cancer patients; however, it is not always effective. TP53 protein plays a differential role in response to DNA-damaging agents and taxanes. W...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kupryjanczyk, Jolanta, Kraszewska, Ewa, Ziolkowska-Seta, Izabela, Madry, Radoslaw, Timorek, Agnieszka, Markowska, Janina, Stelmachow, Jerzy, Bidzinski, Mariusz
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2268700/ https://www.ncbi.nlm.nih.gov/pubmed/18230133 http://dx.doi.org/10.1186/1471-2407-8-27

Ejemplares similares

Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen
por: Kupryjańczyk, J, et al.
Publicado: (2003)

TP53 status determines clinical significance of ERBB2 expression in ovarian cancer
por: Kupryjańczyk, J, et al.
Publicado: (2004)

Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients
por: Felisiak-Golabek, Anna, et al.
Publicado: (2011)

Spontaneous apoptosis in ovarian carcinomas: a positive association with p53 gene mutation is dependent on growth fraction
por: Kupryjánczyk, J, et al.
Publicado: (2000)

Hypersensitivity Reactions to Platinum Agents and Taxanes
por: Tsao, Lulu R., et al.
Publicado: (2021)

TP53 oncomorphic mutations predict resistance to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma
por: BRACHOVA, PAVLA, et al.
Publicado: (2014)

Platinum drugs and taxanes: can we overcome resistance?
por: Sazonova, Elena V., et al.
Publicado: (2021)

Taxanes and platinum derivatives impair Schwann cells via distinct mechanisms
por: Imai, Satoshi, et al.
Publicado: (2017)

Identification and Characterization of a New Platinum-Induced TP53 Mutation in MDAH Ovarian Cancer Cells
por: Lorenzon, Ilaria, et al.
Publicado: (2019)

Palliative chemotherapy in carcinoma penis: Does platinum and taxane combination holds a promise?
por: Patil, Vijay M, et al.
Publicado: (2014)

Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes
por: Tsyganov, Matvey Mihajlovich, et al.
Publicado: (2022)

Comparison of Efficacy and Safety of Taxanes Plus Platinum and Fluorouracil Plus Platinum in the First-Line Treatment of Esophageal Cancer: A Systematic Review and Meta-Analysis
por: Zhao, Yue, et al.
Publicado: (2022)

Effects triggered by platinum nanoparticles on primary keratinocytes
por: Konieczny, Piotr, et al.
Publicado: (2013)

Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer
por: Liu, Ying, et al.
Publicado: (2015)

Risk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapy
por: Molassiotis, Alex, et al.
Publicado: (2019)

Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI
por: Lankester, K J, et al.
Publicado: (2005)

Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane Treatment
por: li, Meiying, et al.
Publicado: (2015)

Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells
por: Mikuła-Pietrasik, Justyna, et al.
Publicado: (2018)

Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors
por: Knoerl, Robert, et al.
Publicado: (2021)

Effect of XPD and TP53 Gene Polymorphisms on the Risk of Platinum-Based Chemotherapy Induced Toxicity in Bangladeshi Lung Cancer Patients
por: Nairuz, Tahsin, et al.
Publicado: (2021)

Aberrant Promoter Methylation of Caveolin-1 Is Associated with Favorable Response to Taxane-Platinum Combination Chemotherapy in Advanced NSCLC
por: Brodie, Seth A., et al.
Publicado: (2014)

Survival benefit of taxane plus platinum in recurrent ovarian cancer with non-clear cell, non-mucinous histology
por: Kajiyama, Hiroaki, et al.
Publicado: (2014)

Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane
por: Satake, Hironaga, et al.
Publicado: (2018)

Maintenance chemotherapy after 6 cycles of platinum-doublet regimen in anthracycline-and taxane-pretreated metastatic breast cancer
por: Joung, Eun Kyo, et al.
Publicado: (2021)

Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review
por: Tian, Hao, et al.
Publicado: (2021)

Cyclooxygenase-2 immunohistochemical expression in serrated polyps of the colon
por: Kiedrowski, Miroslaw, et al.
Publicado: (2014)

Survival outcomes of adjuvant taxanes, platinum plus fluoropyrimidines versus platinum and fluoropyrimidines for gastric cancer patients after D2 gastrectomy: a retrospective propensity score-matched analysis
por: Wu, Lili, et al.
Publicado: (2021)

Platinum
Publicado: (1860)

Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
por: Penson, Richard T., et al.
Publicado: (2020)

Evaluation of selected ultrasonographic parameters and marker levels in the preoperative differentiation of borderline ovarian tumors and ovarian cancers
por: Sobiczewski, Piotr, et al.
Publicado: (2012)

Prognostic Factors of Second and Third Line Chemotherapy Using 5-FU with Platinum, Irinotecan, and Taxane for Advanced Gastric Cancer
por: Park, Ji Soo, et al.
Publicado: (2011)

Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis
por: Lee, J, et al.
Publicado: (2013)

Erratum: Thermal Expansion of Platinum and Platinum-Rhodium Alloys
por: Edsinger, RE, et al.
Publicado: (2014)

Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
por: Uno, Kaname, et al.
Publicado: (2022)

Platinum Amalgam
por: Chase,
Publicado: (1872)

About Platinum
Publicado: (1890)

The Shortage of Platinum
Publicado: (1916)

Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group
por: Ray-Coquard, I, et al.
Publicado: (2009)

Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes
por: Pecorelli, S., et al.
Publicado: (2010)

Genome-Wide Study of Response to Platinum, Taxane, and Combination Therapy in Ovarian Cancer: In vitro Phenotypes, Inherited Variation, and Disease Recurrence
por: Fridley, Brooke L., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ssc0nov5nfrkbjtenh7mh5upk1